165 related articles for article (PubMed ID: 37230760)
1. Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry.
Correll CK; Stryker S; Collier D; Phillips TA; Dennos AC; Balevic SJ; Beukelman T;
RMD Open; 2023 May; 9(2):. PubMed ID: 37230760
[TBL] [Abstract][Full Text] [Related]
2. The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes.
Zisman D; Gladman DD; Stoll ML; Strand V; Lavi I; Hsu JJ; Mellins ED;
J Rheumatol; 2017 Mar; 44(3):342-351. PubMed ID: 28148698
[TBL] [Abstract][Full Text] [Related]
3. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Beukelman T; Lougee A; Matsouaka RA; Collier D; Rumsey DG; Schenfeld J; Stryker S; Twilt M; Kimura Y;
Pediatr Rheumatol Online J; 2021 Aug; 19(1):131. PubMed ID: 34419107
[TBL] [Abstract][Full Text] [Related]
4. Adiposity in Juvenile Psoriatic Arthritis.
Samad A; Stoll ML; Lavi I; Hsu JJ; Strand V; Robinson TN; Mellins ED; Zisman D;
J Rheumatol; 2018 Mar; 45(3):411-418. PubMed ID: 29247150
[TBL] [Abstract][Full Text] [Related]
5. Juvenile Psoriatic Arthritis: A Report from the GRAPPA 2017 Annual Meeting.
Zisman D; Stoll ML; Butbul Aviel Y; Mellins ED
J Rheumatol Suppl; 2018 Jun; 94():11-16. PubMed ID: 29858347
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
[TBL] [Abstract][Full Text] [Related]
7. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
8. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
[TBL] [Abstract][Full Text] [Related]
9. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
Kimura Y; Grevich S; Beukelman T; Morgan E; Nigrovic PA; Mieszkalski K; Graham TB; Ibarra M; Ilowite N; Klein-Gitelman M; Onel K; Prahalad S; Punaro M; Ringold S; Toib D; Van Mater H; Weiss JE; Weiss PF; Schanberg LE;
Pediatr Rheumatol Online J; 2017 Apr; 15(1):23. PubMed ID: 28399931
[TBL] [Abstract][Full Text] [Related]
10. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
[TBL] [Abstract][Full Text] [Related]
11. Occurrence and Risk Factors of Uveitis in Juvenile Psoriatic Arthritis: Data From a Population-based Nationwide Study in Germany.
Baquet-Walscheid K; Rothaus K; Niewerth M; Klotsche J; Minden K; Heiligenhaus A
J Rheumatol; 2022 Jul; 49(7):719-724. PubMed ID: 35034000
[TBL] [Abstract][Full Text] [Related]
12. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
Becker I; Horneff G
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
[TBL] [Abstract][Full Text] [Related]
13. Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study.
Verstegen RHJ; Shrader P; Balevic SJ; Beukelman T; Correll C; Dennos A; Phillips T; Feldman BM;
Arthritis Care Res (Hoboken); 2023 Feb; 75(2):410-422. PubMed ID: 35040593
[TBL] [Abstract][Full Text] [Related]
14. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
15. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.
Janow G; Schanberg LE; Setoguchi S; Hasselblad V; Mellins ED; Schneider R; Kimura Y;
J Rheumatol; 2016 Sep; 43(9):1755-62. PubMed ID: 27307527
[TBL] [Abstract][Full Text] [Related]
16. The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months.
Beukelman T; Kimura Y; Ilowite NT; Mieszkalski K; Natter MD; Burrell G; Best B; Jones J; Schanberg LE;
Pediatr Rheumatol Online J; 2017 Apr; 15(1):30. PubMed ID: 28416023
[TBL] [Abstract][Full Text] [Related]
17. Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project.
Ringold S; Hendrickson A; Abramson L; Beukelman T; Blier PR; Bohnsack J; Chalom EC; Gewanter HL; Gottlieb B; Hollister R; Hsu J; Hudgins A; Ilowite NT; Klein-Gitelman M; Lindsley C; Lopez Benitez JM; Lovell DJ; Mason T; Milojevic D; Moorthy LN; Nanda K; Onel K; Prahalad S; Rabinovich CE; Ray L; Rouster-Stevens K; Ruth N; Shishov M; Spalding S; Syed R; Stoll M; Vehe RK; Weiss JE; White AJ; Wallace CA; Sobel RE
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):529-37. PubMed ID: 25331530
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations.
Leu JH; Shiff NJ; Clark M; Bensley K; Lomax KG; Berezny K; Nelson RM; Zhou H; Xu Z
Paediatr Drugs; 2022 Nov; 24(6):699-714. PubMed ID: 36171515
[TBL] [Abstract][Full Text] [Related]
19. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.
Constantin T; Foeldvari I; Vojinovic J; Horneff G; Burgos-Vargas R; Nikishina I; Akikusa JD; Avcin T; Chaitow J; Koskova E; Lauwerys BR; Calvo Penades I; Flato B; Gamir ML; Huppertz HI; Jaller Raad JJ; Jarosova K; Anton J; Macku M; Otero Escalante WJ; Rutkowska-Sak L; Trauzeddel R; Velez-Sanchez PJ; Wouters C; Wajdula J; Zang C; Bukowski J; Woodworth D; Vlahos B; Martini A; Ruperto N;
J Rheumatol; 2016 Apr; 43(4):816-24. PubMed ID: 26932344
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
Brunner HI; Foeldvari I; Alexeeva E; Ayaz NA; Calvo Penades I; Kasapcopur O; Chasnyk VG; Hufnagel M; Żuber Z; Schulert G; Ozen S; Rakhimyanova A; Ramanan A; Scott C; Sozeri B; Zholobova E; Martin R; Zhu X; Whelan S; Pricop L; Martini A; Lovell D; Ruperto N;
Ann Rheum Dis; 2023 Jan; 82(1):154-160. PubMed ID: 35961761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
